TY - JOUR

T1 - Ceranapril and cerebral blood flow autoregulation

AU - Torup, M

AU - Waldemar, G

AU - Paulson, O B

PY - 1993/4

Y1 - 1993/4

N2 - OBJECTIVE: To investigate the effect of the new angiotensin converting enzyme inhibitor ceranapril (1 mg/kg) on the cerebral blood flow (CBF) autoregulation in normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR).DESIGN: Sixteen WKY rats and 16 SHR were given ceranapril 1 mg/ml intravenously and compared with two untreated control groups (n = 16). The rats were furthermore divided into subgroups of eight to study the upper and lower limits of autoregulation separately.METHODS: CBF was measured using the intracarotid xenon-133 injection technique. The arterial blood pressure was raised stepwise by noradrenaline or lowered stepwise by controlled bleeding, in order to study CBF over a range of mean arterial pressure (MAP) values.RESULTS: Baseline MAP was significantly lower in the WKY rat group than in the SHR group. There was no significant difference in baseline CBF between the treated and the untreated groups. Following ceranapril administration, baseline MAP was reduced by 10 mmHg in WKY rats and by 20 mmHg in SHR, and the limits of CBF autoregulation were reset at lower blood pressure levels. In WKY rats as well as in SHR, ceranapril significantly reduced the lower blood pressure limit of CBF autoregulation. In both strains the upper limit of CBF autoregulation was reduced significantly.CONCLUSION: Ceranapril preserves CBF autoregulation and significantly shifts the limits of CBF autoregulation towards lower blood pressure values.

AB - OBJECTIVE: To investigate the effect of the new angiotensin converting enzyme inhibitor ceranapril (1 mg/kg) on the cerebral blood flow (CBF) autoregulation in normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR).DESIGN: Sixteen WKY rats and 16 SHR were given ceranapril 1 mg/ml intravenously and compared with two untreated control groups (n = 16). The rats were furthermore divided into subgroups of eight to study the upper and lower limits of autoregulation separately.METHODS: CBF was measured using the intracarotid xenon-133 injection technique. The arterial blood pressure was raised stepwise by noradrenaline or lowered stepwise by controlled bleeding, in order to study CBF over a range of mean arterial pressure (MAP) values.RESULTS: Baseline MAP was significantly lower in the WKY rat group than in the SHR group. There was no significant difference in baseline CBF between the treated and the untreated groups. Following ceranapril administration, baseline MAP was reduced by 10 mmHg in WKY rats and by 20 mmHg in SHR, and the limits of CBF autoregulation were reset at lower blood pressure levels. In WKY rats as well as in SHR, ceranapril significantly reduced the lower blood pressure limit of CBF autoregulation. In both strains the upper limit of CBF autoregulation was reduced significantly.CONCLUSION: Ceranapril preserves CBF autoregulation and significantly shifts the limits of CBF autoregulation towards lower blood pressure values.

KW - Angiotensin-Converting Enzyme Inhibitors/pharmacology

KW - Animals

KW - Blood Pressure/drug effects

KW - Cerebrovascular Circulation/drug effects

KW - Homeostasis/drug effects

KW - Hypertension/drug therapy

KW - Male

KW - Organophosphorus Compounds/pharmacology

KW - Proline/analogs & derivatives

KW - Rats

KW - Rats, Inbred SHR

KW - Rats, Inbred WKY

KW - Time Factors

U2 - 10.1097/00004872-199304000-00010

DO - 10.1097/00004872-199304000-00010

M3 - Journal article

C2 - 8390507

VL - 11

SP - 399

EP - 405

JO - Journal of Hypertension, Supplement

JF - Journal of Hypertension, Supplement

SN - 0952-1178

IS - 4

ER -